

Adverse Reaction Reporting Scoreboard

Food and Drugs Authority Safety Monitoring Department/ National Pharmacovigilance Center

Outlook of Regional Performance

Overview of Regional Performance

The Safety Monitoring Department/ National Pharmacovigilance Center of the Food and Drugs Authority (FDA) publishes the Adverse Reaction Reporting Scoreboard every two months to offer quantitative information on the training initiatives and individual case safety reports (ICSRs) received from the sixteen regions. To promote better diagnosis, management and reporting safety issues, the scoreboard is intended to compare reporting trends of adverse reactions to medications, vaccinations and other health-related issues at the regional levels. It is anticipated that this will contribute to increasing the number of adverse reactions that are reported to assist identify new safety signals for marketed medications, vaccines, and other health goods.

Pharmacovigilance Training Programs

The FDA had 116 pharmacovigilance (PV) training programs between May to June 2025 in the 16 regions with a total of 3,771 participants. Figure 1 shows the performance of the regions in terms of the number of PV training programs. The Greater Accra region leads the chart with 16 PV training programs followed by the Bono and Bono East regions, with 14 training programs each.



DA/VVC/SMD/VGU/25/011

June 2025




Fig. 1: Number of PV training programs organized in the regions May – June 2025.

Figure 2 shows the percentage of the professional backgrounds of the participants trained during the PV training programs. Most of the participants (37.3%) were students healthcare professionals.




Fig. 2: Professional background of participants for the PV training programs in percentage.



DA/VVC/SMD/VGU/25/011

June 2025

Adverse Reactions Reported

Four hundred and ninety-one (491) ICSRs were received for medicines, vaccines, and other health products during the period under review. The Bono East region recorded the highest absolute number of reports (Figure 3) followed by the Eastern region. The Bono East region also recorded the highest reporting rate of 98 reports per 1,000,000 population followed by the Ahafo region with a reporting rate of 49 reports per 1,000,000 (Figure 4) based on the 2021 population and housing census.




Fig. 3. Number of adverse reaction reports received in the region.



DA/VVC/SMD/VGU/25/011

June 2025




Fig. 4: Regional reporting rate per 1,000,000 population (using the 2021 Population and Housing Census)

You may reach out to the Safety Monitoring Department on the underlisted contacts for information on the safety of medicines, vaccines, blood and blood products, medical devices and other regulated health products:

Telephone : 024 4310 297

Email : drug.safety@fda.gov.gh